Astellas Pharma Statistics
Total Valuation
Astellas Pharma has a market cap or net worth of 23.20 billion. The enterprise value is 26.11 billion.
| Market Cap | 23.20B |
| Enterprise Value | 26.11B |
Important Dates
The next estimated earnings date is Tuesday, February 3, 2026.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
| Current Share Class | 1.79B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.07% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 53.37% |
| Float | 1.79B |
Valuation Ratios
The trailing PE ratio is 27.50.
| PE Ratio | 27.50 |
| Forward PE | n/a |
| PS Ratio | 1.71 |
| PB Ratio | 2.13 |
| P/TBV Ratio | 21.69 |
| P/FCF Ratio | 9.38 |
| P/OCF Ratio | 8.59 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.27, with an EV/FCF ratio of 10.56.
| EV / Earnings | 30.94 |
| EV / Sales | 2.03 |
| EV / EBITDA | 7.27 |
| EV / EBIT | 11.13 |
| EV / FCF | 10.56 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.46.
| Current Ratio | 1.03 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | 1.32 |
| Debt / FCF | 2.02 |
| Interest Coverage | 28.40 |
Financial Efficiency
Return on equity (ROE) is 7.95% and return on invested capital (ROIC) is 9.58%.
| Return on Equity (ROE) | 7.95% |
| Return on Assets (ROA) | 6.68% |
| Return on Invested Capital (ROIC) | 9.58% |
| Return on Capital Employed (ROCE) | 17.37% |
| Revenue Per Employee | 993,958 |
| Profits Per Employee | 61,848 |
| Employee Count | 13,643 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 1.32 |
Taxes
In the past 12 months, Astellas Pharma has paid 80.61 million in taxes.
| Income Tax | 80.61M |
| Effective Tax Rate | 8.72% |
Stock Price Statistics
The stock price has increased by +15.33% in the last 52 weeks. The beta is 0.07, so Astellas Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.07 |
| 52-Week Price Change | +15.33% |
| 50-Day Moving Average | 10.73 |
| 200-Day Moving Average | 10.71 |
| Relative Strength Index (RSI) | 57.39 |
| Average Volume (20 Days) | 1,628 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Astellas Pharma had revenue of 13.56 billion and earned 843.79 million in profits. Earnings per share was 0.47.
| Revenue | 13.56B |
| Gross Profit | 11.02B |
| Operating Income | 2.49B |
| Pretax Income | 924.40M |
| Net Income | 843.79M |
| EBITDA | 3.80B |
| EBIT | 2.49B |
| Earnings Per Share (EPS) | 0.47 |
Balance Sheet
The company has 1.94 billion in cash and 5.00 billion in debt, giving a net cash position of -3.06 billion.
| Cash & Cash Equivalents | 1.94B |
| Total Debt | 5.00B |
| Net Cash | -3.06B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 10.90B |
| Book Value Per Share | 6.08 |
| Working Capital | 293.12M |
Cash Flow
In the last 12 months, operating cash flow was 2.70 billion and capital expenditures -227.38 million, giving a free cash flow of 2.47 billion.
| Operating Cash Flow | 2.70B |
| Capital Expenditures | -227.38M |
| Free Cash Flow | 2.47B |
| FCF Per Share | n/a |
Margins
Gross margin is 81.28%, with operating and profit margins of 18.39% and 6.22%.
| Gross Margin | 81.28% |
| Operating Margin | 18.39% |
| Pretax Margin | 6.82% |
| Profit Margin | 6.22% |
| EBITDA Margin | 28.06% |
| EBIT Margin | 18.39% |
| FCF Margin | 18.24% |
Dividends & Yields
This stock pays an annual dividend of 0.51, which amounts to a dividend yield of 4.20%.
| Dividend Per Share | 0.51 |
| Dividend Yield | 4.20% |
| Dividend Growth (YoY) | 1.57% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 106.09% |
| Buyback Yield | 0.07% |
| Shareholder Yield | 4.27% |
| Earnings Yield | 3.64% |
| FCF Yield | 10.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Astellas Pharma has an Altman Z-Score of 2.17 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.17 |
| Piotroski F-Score | 6 |